Bruker Corporation Q3 2024 Earnings Report

Bruker (NASDAQ: BRKR), a global scientific instruments company, reported a 16.4% revenue increase year-over-year in Q3 2024, totaling $864.4 million. This growth was driven by both organic growth (3.1%) and acquisitions (12.5%).

Financial Highlights

• Revenue: Q3 2024 revenue rose to $864.4 million.
• EPS: The non-GAAP diluted EPS for Q3 was $0.60, down from $0.74 a year prior.
• Full-year Guidance: The company adjusted the full-year 2024 guidance downwards due to reduced optimism in the biopharma sector and Chinese market demand, expecting CER revenue growth of about 13%.

Key Takeaways

• Growth Drivers: Organic and acquisition-driven growth contributed to a positive performance in diagnostics and semiconductor metrology.
• Challenges: Slower recovery in biopharma and China prompted a cautious outlook.
• Future Strategy: Focus on operational improvements and innovation, particularly in single-cell spatial molecular diagnostics and lab automation.

Company Outlook

• Expected full-year revenue between $3.34 billion and $3.37 billion.
• Anticipates revenue growth from Chinese stimulus orders in late-2024.
• Management aims for operational break-even in Cellular Analysis by 2026.

Summary

Despite sustained revenue growth, Bruker faced challenges from weaker biopharma and China markets, leading to a cautious outlook for the fiscal year ahead with a focus on innovation and improvement.